CoreMedic Receives Additional Series B Funding for ChordArt TMVr System

February 11, 2025—CoreMedic GmbH announced it received a new investment from MIG Capital AG for a Series B extension round for the CoreMedic ChordArt transcatheter mitral valve repair (TMVr) system.

According to CoreMedic, this additional funding will allow the company to complete its in-progress first-in-human trial of the ChordArt device. Additionally, the company will continue to build upon its medical advisory and international clinical community in preparation for expanding to a global clinical program.

CoreMedic describes the ChordArt TMVr system as a catheter system designed to deliver implants percutaneously, allowing interventions in high-risk and asymptomatic patients, who are not eligible for treatment via open heart surgery. It is intended to improve chorda repair procedures across all crucial parameters, including reducing patient trauma, procedure time, and complexity; shortening recovery time; and expanding treatment options for those previously ineligible for conventional surgery.